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The loss of HBII-52 and related C/D box small nucleolar RNA (snoRNA) expression units have been implicated
as a cause for the Prader–Willi syndrome (PWS). We recently found that the C/D box snoRNA HBII-52 changes
the alternative splicing of the serotonin receptor 2C pre-mRNA, which is different from the traditional C/D box
snoRNA function in non-mRNA methylation. Using bioinformatic predictions and experimental verification, we
identified five pre-mRNAs (DPM2, TAF1, RALGPS1, PBRM1 and CRHR1) containing alternative exons that are
regulated by MBII-52, the mouse homolog of HBII-52. Analysis of a single member of the MBII-52 cluster of
snoRNAs by RNase protection and northern blot analysis shows that the MBII-52 expressing unit generates
shorter RNAs that originate from the full-length MBII-52 snoRNA through additional processing steps.
These novel RNAs associate with hnRNPs and not with proteins associated with canonical C/D box
snoRNAs. Our data indicate that not a traditional C/D box snoRNA MBII-52, but a processed version lacking
the snoRNA stem is the predominant MBII-52 RNA missing in PWS. This processed snoRNA functions in
alternative splice-site selection. Its substitution could be a therapeutic principle for PWS.
INTRODUCTION
It has been estimated that 95% of human multi-exon genes
undergo alternative splicing (1,2), indicating that this
pre-mRNA processing step is central for human gene expression.
Unlike promoter activity that is predominantly reflected in the
abundance of transcripts, alternative splicing influences the struc-
ture of the mRNAs and their encoded proteins. As a result, it
influences binding properties, intracellular localization, enzy-
matic activity, protein stability and post-translational modifi-
cation of numerous gene products (reviewed in 3).
We recently found that usage of the alternative exon Vb of the
serotonin receptor 2C (HTR2C) is regulated by expressing a C/D
box snoRNA, HBII-52. SnoRNAs are small nuclear RNAs that
can be detected in the nucleolus. They reside in introns from
which they are released through nuclease action during the pro-
cessing of the host pre-mRNA. On the basis of their sequence,
snoRNAs can be subdivided into C/D and H/ACA snoRNAs.
C/D box snoRNAs have C and D boxes as characteristic
sequence elements at the ends of the RNA. The 50 and 30 ends
of the snoRNA form a short stem that precedes the C and D
boxes, which together form a kink-turn (K-turn) structure (4).
A well-understood function attributed to C/D box snoRNAs
is the guiding of 20-O-methylation in ribosomal, transfer and
small nuclear RNAs. This activity is achieved through the for-
mation of a specific RNA:RNA duplex between the snoRNA
and the target. Most snoRNAs contain two regions to interact
with other RNAs, termed the antisense boxes. Each antisense
box exhibits sequence complementarity to its target and forms
a short, transient double strand with it. On the target RNA, the
nucleotide that base pairs with the fifth snoRNA nucleotide
upstream of the snoRNA D-box is methylated on the
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20-O-hydroxyl group (reviewed in 5). Several snoRNAs are
complementary to pre-rRNA, but the rRNA is not
20-O-methylated at the predicted positions (6). Recently,
numerous C/D box snoRNAs were discovered that show no
clear sequence complementarity to other non-mRNAs,
suggesting that C/D box snoRNAs might have functions
other than 20-O-methylation (7). One of these ‘orphan’ C/D
box snoRNAs is HBII-52 (SNORD 115). It is expressed
from the SNURF–SNRPN locus. Loss of expression from
this locus is the most likely cause for Prader–Willi syndrome
(PWS) (8), which was supported by the recent finding that a
microdeletion containing only snoRNAs causes PWS (9).
HBII-52 exhibits sequence complementarity to an alternative
exon of the human serotonin receptor 2C mRNA and
changes alternative splicing of this pre-mRNA (HTR2C) in
transfection experiments. This change has also been observed
in brain tissue from PWS patients (10) and a mouse model
lacking MBII-52 snoRNAs shows differences in pre-mRNA
processing of the serotonin receptor (11). Finally, it was
reported that an increase of C/D box snoRNA expression
from the 15q11–q13 region leads to autistic phenotypes in
mice, which further suggests that snoRNAs play an important
role in gene regulation (12).
PWS is a congenital disease with an incidence of about 1 in
8000–20 000 live births. PWS is the most common genetic
cause of marked obesity in humans. The excess weight
makes PWS the most frequent genetic cause for type II dia-
betes (8). Early PWS is characterized by a failure to thrive,
feeding difficulties and hypogonadism. Later, the patients
are characterized by short stature and develop mild to moder-
ate mental retardation, behavioral problems and hyperphagia
that lead to severe obesity. Children with PWS show low
levels of growth hormone, IGF-I and insulin as well as elev-
ated levels of ghrelin (13–15) and often exhibit central
adrenal insufficiency (16). Subsequently, growth hormone
substitution was approved for the treatment of children with
PWS (17).
PWS is caused by the loss of gene expression from a mater-
nally imprinted region on chromosome 15q11–q13 (reviewed
in 8). The SNURF–SNRPN locus in the 15q11–q13 region
plays a major role in PWS, and its deletion causes PWS-like
symptoms in mouse models (18). The SNURF–SNRPN
locus spans more than 460 kb and contains at least 148
exons (19). Ten exons in the 50 part of the gene are transcribed
into a bicistronic mRNA that encodes the SNURF (SmN
upstream reading frame) and the SmN (small RNP in
neurons) protein. The locus harbors a bipartite imprinting
center that silences most maternal genes of the PWS critical
region. Owing to this imprinting, the SNURF–SNRPN
pre-mRNA is expressed only from the paternal allele. The
large 30-UTR region of the SNURF–SNRPN locus harbors
clusters of the C/D box snoRNAs HBII-85 and HBII-52 that
are present in 24 and 47 copies, respectively. In addition,
the region harbors single copies of other C/D box snoRNAs:
HBII-13, HBII-436, HBII-437, HBII-438A and HBII-438B.
Recent evidence suggests that the HBII-85 and HBII-52
snoRNA clusters are expressed as two transcriptional units
(20). The highly conserved snoRNAs are flanked by poorly
conserved non-coding exons, suggesting that the functional
relevant products of the locus are snoRNAs, not the flanking
exons. The expression of these snoRNAs is tissue-specific.
HBII-52 could be detected only in brain, whereas other
snoRNAs from the SNURF–SNRPN locus are also expressed
in non-brain tissues (reviewed in 21).
Here, we analyzed the function of the mouse ortholog of
HBII-52, MBII-52. We found that it regulates alternative
pre-mRNA processing of at least five more genes. The unit
expressing MBII-52 expresses smaller RNAs that appear to
be nuclease processing products of the full-length MBII-52
snoRNA. We termed these shorter RNAs psnoRNAs for pro-
cessed snoRNAs. psnoRNAs associate with hnRNPs and not
with the known C/D box snoRNA binding proteins. We postu-
late that psnoRNAs recognize target RNAs by sequence com-
plementarity and influence splice-site selection by interfering
with splicing regulatory proteins acting on pre-mRNA.
RESULTS
New targets for MBII-52
The recent finding that HBII-52 regulates alternative splicing
of the 5-HT2C receptor (10) raised the question whether
there are other targets for this snoRNA. The antisense boxes
of the 47 human copies of HBII-52 show up to three sequence
variations from their 18 nt consensus sequences (21). We
tested HBII-52 variants with one, two, three and five mutations
in their antisense box for their ability to change alternative
splicing of exon Vb of the serotonin receptor. We found that
a snoRNA with three mismatches can still promote exon Vb
inclusion (Supplementary Material, Fig. S1). There is no stat-
istically significant change when five mismatches are present
in the antisense box. This argues that naturally occurring
HBII-52 variants with up to three mismatches between anti-
sense box and target region can influence pre-mRNA proces-
sing of the serotonin receptor.
In order to uncover additional targets of HBII-52, we per-
formed a computational screen. Because the mode of inter-
action between HBII-52 and its targets is not yet known, we
based our analysis on the constraints on snoRNA:rRNA inter-
actions leading to ribose methylation in ribosomal targets (22).
Concretely, we started by extracting an 18-nt-long antisense
element upstream of the D box of MBII-52. We defined as a
putative target site of MBII-52 a genomic region that can
either form a perfect stem of length at least 10 bp or form a
duplex of low free energy (below 215 kcal/mol) with the
MBII-52 antisense element, with the duplex satisfying
additional constraints. Minimum free energy duplexes were
predicted with RNAhybrid (23) allowing G:U wobble in
addition to canonical base pairing. The constraints on the
duplexes were that (i) loops in the duplex were limited to
maximum two nucleotides in either the target sequence or in
antisense element and (ii) only up to three unpaired nucleo-
tides in any of the sequences was allowed. Finally, similar
to approaches previously employed to predict miRNA
targets, we required that the predicted target site be conserved
across mammalian species. More specifically, we extracted the
regions in the human, rhesus macaque, cow and dog that are
orthologous to the predicted HBII-52 target sites in human
and we determined whether they would also be predicted as
target sites. As the antisense box of HBII-52 is highly con-
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served in mammals, we compared all orthologous genes to the
human antisense box sequence. Our final set of predictions
included only putative MBII-52 target sites that were con-
served in all of these other species. We obtained 457 such
sites, 222 of which are in close proximity (200 nt) or within
known exons. The predictions are available at http://www.
mirz.unibas.ch/MBII-52/.
We next tested more than 100 computational predictions
experimentally. Neuro2A cells were transfected with either
MBII-52 or MBII-52mut, an MBII-52 variant with a
scrambled antisense box (10), and the isolated RNA was ana-
lyzed by RT–PCR, using primers in the flanking constitutive
exons. As shown in Figure 1, we observed a change in alterna-
tive splicing patterns in the DPM2, TAF1, RALGPS1, PBRM1
and CRHR1 pre-mRNAs. MBII-52 overexpression promoted
either inclusion or skipping of the different exons. Their
sequences and the complementarity to MBII-52 are shown in
Table 1. These data suggest that MBII-52 expression
changes alternative splicing of several endogenous pre-
mRNAs.
MBII-52 changes alternative splicing of targeted
pre-mRNAs in reporter gene assays
In the next step of the analysis, we determined whether
alternative exons that are influenced by MBII-52 expression
show this dependency also in a heterologous system, where
they are surrounded by a different RNA context. We cloned
the MBII-52 regulated exons into an exon-trap vector, where
they were flanked by constitutively spliced insulin exons.
All constructs were cloned into pSpliceExpress, a system
that we developed previously (24).
The reporter genes were cotransfected with MBII-52
expression constructs into Neuro2A cells and the splicing pat-
terns were analyzed by RT–PCR. As shown in Figure 2, we
observed for the five splicing events identified in endogenous
genes a similar dependency on MBII-52 expression. The
expression of MBII-85 snoRNA and C and D box mutants
of MBII-52 (MBII-52cC,cD) did not show a significant
effect on the alternative exons, suggesting that the effect is
specific for MBII-52. With the exception of PBRM1, the
reporter minigenes followed the splicing pattern of the
endogenous genes. In the endogenous PBRM1 gene,
MBII-52 promoted both inclusion and skipping of two exons
located in a cluster of alternatively spliced cassette exons. In
the heterologous system, we observe only the skipping event
for PBRM1. This difference is most likely due to the presence
of strong insulin exons in pSpliceExpress that interfere with
the arrangement of regulatory sequences in this cluster of mul-
tiple alternative cassette exons. Finally, we created a series of
compensatory mutations in the antisense box of MBII-52 and
the snoRNA complementarity regions (snoCR) of its targets.
These experiments proved inconclusive, as in most cases
mutating the snoCR resulted in strong exon activation that
was no longer susceptible to regulation (data not shown).
Together, these data suggest that after being transferred into
a heterologous gene context at least five alternative exons are
influenced by MBII-52 expression.
A mouse model of PWS shows changes in the predicted
exons
To address the physiological significance of our data, we
asked whether MBII-52 influences alternative splicing of the
identified target genes in vivo and analyzed RNA samples
from the TgPWS mouse model. TgPWS mice have a pater-
nally derived deletion of the PWS critical region that contains
the SNURF–SNRPN locus. They show hormonal and meta-
bolic defects resembling those of human newborns with
PWS (18). As a larger locus is deleted, in addition to MBII-
52, the mice do not express MBII-85 and other snoRNAs
from the Prader–Willi critical region.
We compared RNA from newborn TgPWS mice with RNA
from littermates expressing the region. As shown in Figure 3,
we found that the mouse knockout systems recapitulates a
dependency of alternative splicing on the presence of
MBII-52. However, the overall splicing patterns of the
endogenous genes are different in mouse brain and Neuro2A
cells. This most likely reflects the presence of numerous cell
types in brain that show different splicing patterns. Despite
this limitation, the presence of MBII-52 promotes exon
inclusion in the alternative exons with a complementarity to
MBII-52 of the DPM2 and PBRM1 pre-mRNAs and promotes
skipping of the RALGPS1 and TAF1 exons, similar to the
effect seen in Neuro2A cells. The only discrepancy between
the MBII-52 effects in brain and Neuro2A cells was an
alternative exon of CRHR1 that showed an increase in exon
usage in brain tissue, whereas it showed a decrease in response
to MBII-52 in Neuro2A cells. The regulated alternative
CRHR1 exon is in a cluster of alternative exons and the discre-
pancy could be due to differences in splicing regulators
between brain and Neuro2A cells. Collectively, the data
suggest that the loss of MBII-52 expression influences alterna-
tive splicing of target genes in a physiological context.
MBII-52 is processed into smaller RNAs
The data indicate that MBII-52 expression influences usage of
multiple exons that contain regions with sequence comple-
mentarity to the antisense-box of MBII-52. Four recent
studies reported that H/ACA snoRNAs give rise to smaller
RNAs (25–28). We therefore tested whether the C/D box
snoRNA MBII-52 also gives rise to other RNAs by RNase
protection analysis.
Whereas humans have 47 HBII-52 copies, there are at least
130 copies of MBII-52 snoRNAs in mouse. We used an anti-
sense probe against the MBII-52 copy employed in transfec-
tion experiments described above. This isoform is 87 nt in
length and its sequence is shown in Figure 4D as form
A. In silico analysis shows that this copy shares only an unin-
terrupted stretch of 20 nt in the antisense box region with other
snoRNA isoforms of the MBII-52 cluster. All other regions
show single nucleotide differences that prevent longer pro-
tected fragments. For the analysis, we used an in vitro tran-
scribed, 32P labeled RNA-antisense probe that detects the 87
nt encompassing the full-length snoRNA. Together with
linker and vector sequences, the probe is 175 nt in length.
After hybridization, RNase A and T1 digestion, the fragments
were separated on 15% acrylamide/TBE/8 M urea gels. As
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shown in Figure 4A, lane 1, we observed additional fragments
when total mouse brain RNA was analyzed with this probe. In
agreement with earlier studies, we do not detect expression in
liver (29) (Fig. 4A, lane 9). We then asked whether the
snoRNA expression construct used in Figure 1 is processed
in a similar way. We analyzed total RNA from Neuro2A
cells transfected with the pCMV/MBII-52 expression con-
struct (Fig. 4A, lane 2) and found a similar RNA pattern.
Importantly, the most abundant RNA species from both the
expression construct and brain is shorter than 80 nt (form B,
Figure 1. MBII-52 changes the alternative splicing pattern of predicted targets. Computationally predicted MBII-52 target genes expressed in Neuro2A cells
were analyzed by RT–PCR. Cells were transfected with 1 mg pEGFP-C2, 1 mg of the MBII-52 expressing construct pCMV/MBII-52 (MBII-52) (29) and 1 mg
MBII-52 consensus box mutation, MBII-52 cm, (MBII-52 mut) expressing an antisense box mutation of MBII-52 (10). A representative ethidium
bromide-stained agarose gel is shown. The adjacent diagram shows the part of the genes that was analyzed. Small arrows indicate the location of the
primers used. The MBII-52 complementarity region is indicated by a dot. Numbers in boxes indicate the length of the exons and numbers next to PCR
primers indicate the length of the amplified exon fragment. The structure of the PCR products is indicated by similar shading of exons in cDNA and
genomic DNA. The statistical analysis of at least four independent experiments is shown on the right. Stars indicate the bands that were used for quantification.
The sequences of the regulated exons are shown in Table 1.
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Fig. 4A). SnoRNAs contain C and D boxes that stabilize the
snoRNP. Mutation of these RNA elements abolished the
effect on splicing (Fig. 2). We therefore tested expression
from constructs expressing this mutants and could not detect
any RNA expression (Fig. 4A, lanes 6 and 7), suggesting
that the smaller RNAs (form B, C, D) derive from a precursor
with intact C and D boxes.
It is possible that MBII-52 undergoes nucleotide modifi-
cations that would result in mismatching of an RNase protec-
tion probe and subsequent generation of smaller fragments. To
rule out this possibility, we performed northern blot analysis,
using denaturing 15% PAGE gels. Total RNA from brain,
liver and spleen was probed with MBII-52 antisense RNA cor-
responding to the sequence in Figure 4D, form A. Even after
stringent washing, we see cross-hybridization of MBII-52
with RNAs from liver, spleen and HEK293 cells (Fig. 4B).
This is to be expected, as there are numerous copies of
sequence-related snoRNAs expressed in these tissues (29).
To detect the specific hybridization between MBII-52 form
A and brain RNA, we treated the membrane with RNase A
and RNase T1. The RNase treatment reduced the overall
signal strength, as we had to use a 3-fold longer exposure
time. As shown in Figure 4C, this treatment abolishes the
cross-hybridization with non-brain RNAs. However, this treat-
ment does not abolish the signal from brain RNA tissue that
corresponds in length to RNA forms B–D. Similar to the
RNA protection experiment, the major RNA species is
shorter than 80 nt. This indicates that the protection pattern
observed in the protection assay is due to shorter RNAs and
not the result of nucleotide editing. Unexpectedly, we
observe a distinct pattern of shorter RNAs and not a continu-
ous smear of bands. This finding implies that all of the esti-
mated MBII-52 copies are processed in a similar way,
giving rise to specific metabolically stable short RNAs.
To determine the identity of the novel short RNAs, we
cloned the protected fragments. Total mouse brain RNA was
subjected to RNase protection. Subsequently, the RNases
were removed by Proteinase K treatment and phenol extrac-
tion. The double-stranded RNA was phosphorylated using
T4 kinase, and an adenylated-linker was ligated in the
absence of ATP (30). After gel purification and isolation, an
adapter linker was ligated using T4 DNA ligase. The reaction
was subsequently reverse transcribed, amplified and cloned.
The positive clones are shown in Figure 4D. All shorter
RNAs lack the sequences forming the stem of the snoRNA,
but contain the C and C0 box. The stem conveys complemen-
tarity between the snoRNA ends and stabilizes the snoRNP.
The remaining cloned RNAs are shortened from the 50 and
Figure 1. (Continued)
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30 ends, indicating that they are generated by 30!50 and
50!30 exonuclease activity that stops at the C and C0 boxes.
Together, these data suggest that the expression unit con-
sisting of MBII-52 and its flanking intron and exons gives
rise to several RNAs. These RNAs include the previously
described MBII-52 snoRNA (form A), as well as shorter
RNA species. The major RNA species (form B) expressed
from the MBII-52 cluster lacks the stem box, but still
contain C and D boxes.
MBII-52 derived RNAs do not bind to classical
snoRNA-associated proteins
As we found that the MBII-52 locus gives rise to previously
not described products, we identified the proteins that associ-
ate with these RNAs. We used the affinity between a biotiny-
lated 20-O-methylated oligonucleotide and the antisense box of
MBII-52 to isolate RNAs derived from the MBII-52 locus
(Fig. 5A). Using streptavidin beads, we isolated the MBII-52
snoRNA particle (snoRNP) from nuclear extracts generated
from cells transfected with the MBII-52 expression construct.
Nuclear extract was generated by a scaled-down Dignam pro-
cedure (31). After washing with 100 and 200 mM NaCl, the
captured material was separated by SDS–PAGE and proteins
were identified by mass spectrometry and database matching.
An oligonucleotide against the snoCR of MBII-85 was used as
the control. As shown in Figure 5B, we found that hnRNPs
were associated with the expressed snoRNA. Similar results
were seen with samples obtained from mouse brain nuclear
extracts (data not shown). Repeated experiments using differ-
ent washing and isolation methods to find canonical snoRNP
proteins, such as fibrillarin or NOP56, in pulled-down material
from MBII-52 affinity material failed to identify known
snoRNP-associated proteins.
We determined which RNAs are present in the pulled-down
material and performed RNase protection. As shown in
Figure 4A, lane 4 and 5, we found that the isolates contained the
smaller MBII-52-related RNAs, as well as the full-length
MBII-52 snoRNA. No MBII-52 RNA was pulled-down with the
probe against MBII-85, suggesting the selectivity of the pull-down.
In summary, the findings indicate that the shorter RNAs
assemble with hnRNPs, but not with proteins that have pre-
viously been described to associate with C/D box snoRNAs.
Although the major RNA isoform B contains C and D
boxes, structural hallmarks of C/D box snoRNAs, the compo-
sition of the RNP formed is different from a C/D box snoRNP.
DISCUSSION
The MBII-52 expression unit generates processed
snoRNAs (psnoRNAs)
MBII-52 snoRNAs are expressed from a cluster containing mul-
tiple copies of tandemly arranged snoRNA expression units.
Table 1. Sequence properties of MBII-52 targets
Genes that showed a dependency on MBII-52 expression both on endogenous and reporter gene level are listed using their HUGO nomenclature (columns 1 and
2). Numbers in parentheses indicate the exon length. The sequence of the regulated exon and its surrounding sequence is shown in column 3. Introns are in small
letters, exons in capital letters. The snoRNA complementary region is highlighted in grey and underlined. Column 5 shows the alignment between the MBII-52
antisense box (snoRNA) and its target region.
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Each unit contains phylogenetically poorly conserved exons
that flank an intron which hosts the snoRNA (19). Humans
contain 47 HBII-52 copies and mice at least 130 copies.
Using RNase protection assays, we analyzed the mouse
MBII-52 copy that is most closely related to the copy 27 of
human HBII-52 snoRNA cluster. There is enough sequence het-
erogeneity between the different MBII-52 snoRNA copies that
allows their discrimination in protection assays. Unexpectedly,
the RNase protection assay indicates that the snoRNA gives rise
to other smaller RNAs and that the full-length C/D box snoRNA
is a minor form. The presence of the smaller RNAs could be
verified by northern blot analysis, which further rules out that
signals corresponding to shorter RNAs are caused by the protec-
tion of unrelated RNAs or are caused by RNA editing events
that introduce mismatches to the probe. Finally, we tested ecto-
pical expression of MBII-52 in HEK293 cells that do not
express this snoRNA. The expression construct gives a
similar pattern of shorter RNAs, indicating that they are
derived from the transfected single MBII-52 expressing unit.
The cloning of the shorter RNAs indicates that the major
RNA form expressed from the MBII-52 expression unit is a
73 nt long RNA (form B) that lacks the sequences that form
the snoRNA stem. However, this RNA contains other C/D
box snoRNA elements, such as the C box, D box and antisense
box. This RNA appears to be further shortened by exonuclease
trimming, giving rise to smaller RNAs. The shorter RNAs
can be detected both by northern blot and RNase protection ana-
lyses, indicating that they are metabolically stable. It is possible
that these RNAs are protected from further endonuclease action
by predicted secondary structures. The RNA form D forms a
5 bp stem on its 50 and 30 ends and RNA form C contains a
short stem at its 50 end (Fig. 4D, underlined region). In addition,
the formation of protein complexes is likely to stabilize
the RNAs.
Figure 2. Minigene analysis of MBII-52 target genes. The exons harboring the MBII-52 complementary region were subcloned into the exon trap vector
pSpliceExpress. The structure of the resulting constructs pSE-RALGPS1, pSE-CRHR1, pSE-DPM2, pSE-PBRM1 and pSE-TAF1 as well as the location of
the primers used for RT–PCR analysis is indicated on the left. pEGFP: only an expression construct for GFP is transfected. All other lanes contain 1 mg of
pSE-reporter. MBII-52: cotransfection with 2 and 4 mg of MBII-52 expression construct, MBII-85: cotransfection with 2 and 4 mg of an MBII-85 expression
construct, MBII52cC: cotransfection with 4 mg of a C-box mutant of MBII-52: MBII52cD: cotransfection with 4 mg of a D-box mutant of MBII-52. The structure
of the products is shown schematically on the right, using the same shading scheme as in Figure 1. The usage of alternative exons indicated with a triangle was
statistically evaluated. The comparison between MBII-52 and MBII-85 transfected cells showed statistically significant differences, the P-values of the Student’s
t-test were: DPM2: 0.001, TAF1: 0.023; RALGPS: 0.021; PBRM1: 0.076 and CRHR1: 0.002; (n ¼ 4).
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Ectopic expression of snoRNA mutants suggests that the for-
mation of shorter RNAs depends on intact C and D boxes, which
suggests that they derive from a C/D box snoRNA or pre-
snoRNA structure. A possible scenario is that an unknown
RNase initially removes the stem of the C/D box RNA, which
gives rise to the predominant form B. This form is stabilized
by the presence of the C and D boxes, most likely by binding
to other proteins. Form B is shortened by exonucleases,
giving rise to forms C, D and E that are most likely stabilized
by another stem-loop structure and/or associated proteins.
To obtain insight into proteins associated with these novel
RNAs, we isolated them by affinity purification of RNP
complexes, using a probe that is complementary to the anti-
sense box of MBII-52. We used nuclear extract generated by
the Dignam procedure as starting material. In this method,
most of the nucleolar material is separated in a high-speed
centrifugation step. As the MBII-52-derived snoRNAs are
present in this fraction, they are most likely present in the
nucleoplasm. The major form RNA form B derived from
MBII-52 does not contain the characteristic k-turn, which
most likely prevents its association to Snu13p/15.5 kDa
(4). In agreement with this RNA structure, we could not
detect C/D box snoRNA-associated proteins, such as fibril-
larin, or NOP56 (5) in the isolated material. In contrast,
we identified hnRNPs, including hnRNP A1, A2, TDP-43
and D0 that have been reported to be involved in splice-site
selection. Unexpectedly, in the pull-downed material, we
could still detect RNA forms C and D. These RNAs lack a
complete snoCR that is complementary to the pull-down
probe. Relative to the starting brain material, the RNA
forms C and D are reduced in the pulled down material
(compare Fig. 4A, lanes 1 and 5), but are still detectable.
This suggests that the different RNA forms could be
present within a complex.
We propose to name these shorter RNAs psnoRNAs for pro-
cessed small nucleolar RNAs. PsnoRNAs could represent a
new class of nuclear small RNAs. The psnoRNAs described
here are the first to be derived from C/D box snoRNAs.
MBII-52-derived psnoRNAs regulate splicing of several
pre-mRNAs
We previously found that the expression of the snoRNA
HBII-52 promotes inclusion of exon Vb of the serotonin
receptor 5-HT2C. To investigate whether this represents a
special, unique case or is part of a new regulatory mechanism,
we developed a computational screen that predicted more than
400 putative snoRNA targets. We tested some of these pre-
dicted targets by RT–PCR in transfection assays and further
concentrated on five splicing events that showed consistent
dependency on MBII-52 expression. In contrast to the
5-HT2C receptor pre-mRNA, the pre-mRNAs harboring the
MBII-52-dependent exons are expressed in Neuro2A and
HEK293 cells, which allows us to determine the influence of
MBII-52 expression on the endogenous genes. Also in contrast
to the neuron-specific 5-HT2C system where a splice site had
to be optimized to detect the dependency on MBII-52 (10), the
new alternative exons showed the dependency on MBII-52
expression when analyzed in their endogenous gene context.
The alternative exons were next tested in a heterologous
exon trap system and showed the dependency of MBII-52
when flanked by insulin exons that are controlled by a CMV
promoter. These experiments suggest that MBII-52 RNAs
act on defined parts of the pre-mRNA, in a mechanism that
Figure 3. Comparison of RNA from TgPWS mice lacking MBII-52 expression and control littermates. Total brain samples from TgPWS mice lacking
expression of the Prader–Willi critical region were compared with normal littermates expressing all the snoRNAs from the PWS critical region (control).
Primers similar to Figure 1 were used. The structure of the gene products is indicated similar to Figures 1 and 2. Stars indicate the bands that were used for
comparison. n ¼ 6, other statistical evaluations: P ¼ 0.093, ,0.001, 0.0023, 0.001, 0.05 for DPM2, TAF1, RALGPS1, PBRM1 and CRHR1, respectively.
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is independent of the promoter usage and genomic context.
Together, these data strongly suggest that MBII-52 expression
influences alternative pre-mRNA splicing events.
Expression of MBII-52 causes a small, but statistically sig-
nificant changes in multiple targets. This modest influence on
numerous targets has been observed for other splicing factors,
such as SMN (32) and NOVA (33). Detailed work in the
NOVA system (33) suggested that a splicing factor can
control biological processes by coordinating numerous small
changes and it is possible that MBII-52 fulfills a similar func-
tion. An alignment of the antisense box of MBII-52 and its
experimentally confirmed targets is shown in Supplementary
Data 2. The complementarity between the MBII-52 antisense
box and its targets can be interrupted in multiple positions.
With the exception of the serotonin receptor 5HT2C, there
are always three mismatches in the alignment of the snoCR
and the MBII-52 antisense box. It is interesting that the sero-
tonin pre-mRNA can be edited at three positions within the
snoCR. Taking these editing events into account, the data
suggest that preferably 15 of the 18 nucleotides of the anti-
sense box show complementarity towards its target. It is note-
worthy that we initially concentrated on targets with only one
or two mismatches, but did not find a dependency of these
exons on MBII-52 expression. The data indicate that MBII-52-
derived RNAs need a defined degree of sequence complemen-
tarity towards their targets. This scenario is reminiscent of the
action of U1 snRNP on the 50 splice site, where natural occur-
ring exons rarely show 100% complementarity towards the U1
snRNA, but usually have several mismatches, which cluster in
certain position of the 50 splice site (34).
The existence of psnoRNAs could explain the influence of
MBII-52 expression on splice-site selection in a model illus-
trated in Figure 6. We postulate that the MBII-52 expressing
unit consisting of two non-coding exons flanking an intron
that hosts an snoRNA gives rise to several RNAs. The major
form derived from the expression unit is form B that lacks
Figure 4. MBII-52 is processed into smaller RNAs. (A) RNase protection analysis using a probe detecting the MBII-52 copy used in transfection studies in
Figures 1 and 2. Five microgram of the following total RNAs was hybridized to an MBII-52 antisense probe: (1): total mouse brain, (2): Neuro2A cells trans-
fected with pCMV/MBII-52. Lanes (3–5) are protections from RNPs captured with oligonucleotides against the antisense box (Fig. 5). (3): Affinity captured
RNA from Neuro2A cells expressing MBII-52 using a MBII-52 probe for pull down (pd), (4): affinity captured RNA from Neuro2A expressing MBII-52
using an MBII-85 probe (negative control) and (5): affinity captured RNA from brain using an MBII-52 probe for pull down. Lane 6: RNA from Neuro2A
cells transfected with an expression construct containing a C-box mutant, (7): RNA from Neuro2A cells transfected with an expression construct containing
a D-box mutant, (8): HEK293 cells non-transfected, (9, 10): RNA from liver and yeast. (11): Undigested probe. The marker is a 100 nt RNA base ladder.
(B) Northern blot analysis of MBII-52. Fifteen microgram total RNA from brain, liver, spleen and HEK293 cells was separated on 15% polyacrylamide gels
and probed with a 32P labeled probe for MBII-52. After stringent washing, cross-hybridizing bands in liver, spleen and HEK293 cells still remain. Exposure
was overnight. (C) The filter from (B) was treated with RNase A/T1 and again washed. The cross-hybridizing bands disappear, but the signals corresponding
to smaller bands remain. Exposure was for 3 days. (D) Sequences of the shorter RNAs. The stems and functional boxes are indicated. The clones are ordered
according to their length. Form A corresponds to the published snoRNA MBII-52. Underlined nucleotides in forms C and D indicated predicted stems.
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the snoRNA stem-structure and is associated with hnRNPs,
but not C/D box snoRNA-typical proteins. Form B contains
the antisense box that targets it to other RNAs, including pre-
mRNAs identified in this study. Form B RNA can influence
splice-site selection by competing with existing splicing regu-
latory factors on the pre-mRNA or by bringing the associated
hnRNPs to the targets, similar to a bifunctional oligonucletide.
The longest RNA (form A) has all the hallmarks of a tra-
ditional C/D box snoRNA, but is only a minor fraction of
the RNA expressed. It is likely that this RNA is transported
into the nucleolus, where it can be detected by in situ hybrid-
ization (35). It is not clear what function this RNA has in the
nucleolus, but it could represent a storage form for the for-
mation of the active RNA form B that is released from the
nucleolus according to the physiological needs.
Relevance for PWS
The loss of C/D box snoRNA expression has been postulated
as the underlying mechanism for the development of
Figure 6. Model for MBII-52 action on RNA processing. (1) The PWS critical region contains snoRNAs (thick line) located in introns between non-coding exons
(grey boxes). The snoRNA is characterized by a C box (C), D box (D) and an antisense box (AS), as well as stem-forming sequences (arrows). (2) This unit
generates several RNAs, including the full-length snoRNA that shows its highest concentration in the nucleolus and Cajal bodies (35) as well as several shorter
psnoRNAs (for processed snoRNAs). PsnoRNAs are present in the nucleoplasm where they associate with hnRNPs. (3) PsnoRNAs can change splice-site selec-
tion, most likely by binding to complementary sequences. We postulate that they either remove regulatory proteins from their targets (triangle) or bring in associ-
ated proteins to the exon recognition complex (diamond associated with the small RNA).
Figure 5. Analysis of proteins associated with MBII-52. (A) Experimental strategy: a biotinylated oligonucleotide is used to capture the snoRNP complex. The
oligonucleotide is shown as a line, the complementarity is dashed, biotin is shown as a circle. The RNP complex (boxes) is isolated by streptavidin
(half-circle)-capture from extracts expressing MBII-52 and washed in non-denaturing buffer. The extracts were prepared by transfecting MBII-52 expression
constructs and performing Dignam mini-extracts. (B) Silver stain of a gel with affinity purified RNPs. MBII-52: the RNPs were isolated with a capture-
oligonucleotide against MBII-52. MBII-85: the RNP was isolated with a capture oligonucleotide against MBII-85. Proteins were determined by mass spec-
trometry and are indicated. Sizes in kDa are shown in parentheses.
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PWS (36). This hypothesis was recently supported by a patient
with a 174 584 bp large microdeletion that encompassed only
snoRNAs and their flanking hosting introns and exons. The
deletion led to a Prader–Willi phenotype (9). To date, the
only published RNAs expressed from the 174 584 bp region
are snoRNAs and fragments of their surrounding non-coding
exons.
The idea that the loss of snoRNA expression is central to
PWS is further supported by genetic evidence that ruled out
proteins encoded by MKRN3, MAGEL2 and NDN genes
expressed in the Prader–Willi critical region (37). The
174 584 bp microdeletion removes the snoRNAs HBII-438A,
-85 and 23 of the 47 HBII-52 copies from the paternally
expressed allele. The only snoRNA that was totally removed
by the microdeletion was MBII-85, which let to the suggestion
that MBII-85 loss is the major reason for PWS. However,
there is evidence that HBII-85 and HBII-52 are expressed by
two transcriptional units (20). As the 174 584 bp micordele-
tion contains the 50 end of the HBII-52 cluster, it could
harbor transcriptional elements necessary for proper HBII-52
expression. Furthermore, in the majority of cases, the com-
plete SNURF–SNRPN locus is deleted (8). The contribution
of HBII-85 and HBII-52 loss to PWS is therefore not clear.
Our findings indicate that the SNURF–SNRPN locus not
only gives rise to typical C/D box snoRNAs, but generates
shorter psnoRNAs. The northern blot analysis indicates that
all of the at least 130 MBII-52 copies are processed in a
similar manner. The major RNA form from the MBII-52
cluster is not the canonical C/D box snoRNA, but a shorter
RNA form, most likely similar to psnoRNA form
B. psnoRNAs are associated with hnRNPs and could have
multiple functions by targeting these proteins to other
RNAs. It is not clear whether several psnoRNAs lacking the
antisense box use other RNA parts for targeting or have non-
related functions.
The loss of the regulatory psnoRNAs could be a significant
contribution to the etiology of PWS and substitution of the
short psnoRNAs could be a therapeutic principle for the
disease.
MATERIALS AND METHODS
Transfection experiments were performed using Ca-phosphate
method as described (38).
The construction of reporter minigenes was done by using
recombination between pSpliceExpress, an exon-trap vector
and BAC-derived PCR fragments that encompassed the
alternative exons, as previously described (24).
Pull-down experiments were performed using Dignam-
derived miniextracts (31).
RNase protection analysis was performed using the Ambion
RNase protection kit using uniformly 32P-labeled probes.
Cloning of the psnoRNAs was performed as follows:
100 mg of total brain RNA, isolated by the Trizol method
was protected using 3  106 cpm of an MBII-52 antisense
probe. Hybridization was overnight. Single-stranded RNA
was digested with RNase A/T1 (Ambion, dilution 1:100) for
1 h at 378C and RNases were subsequently removed by
100 mg/ml Proteinase K treatment for 1 h. Following phenol
extraction and precipitation, RNAs were separated on a 15%
acrylamide, 8 M urea gel, exposed overnight and the appropri-
ate bands were excised, crushed, eluted overnight in 3 M
ammonium acetate/1% SDS and recovered by precipitation.
The first RNA linker was 50rAppCTGTAGGCACCATCA
AT/3ddC. It was ligated for 2 h in a 20 ml reaction in 50 mM
HEPES pH 8.3, 10 mM MgCl2, 3.3 mM DTT, 10 mg/ml BSA,
8.3 v/v glycerol and 20 U RNA ligase. The reaction was
again separated by a 15% acrylamide, 8 M urea gel, bands
excised, crushed and eluted overnight. The second RNA
linker was 50-AmMC6/GCTCCAGAATTCGGACCCGAr
GrUrGrCrCrUrArCrArG. It was ligated at 188C in 1 ligase
buffer using T4 DNA ligase overnight. The reaction was
reverse transcribed, PCR amplified and subcloned. Positive
clones were isolated using colony hybridization and
sequenced.
Primers for PCR detection were: CRHR1: Mm
NEWCRHR1F CCAGGATCAGCAGTGTGAGA; MmNEW
CRHR1R AGTGGCCCAGGTAGTTGATG; TAF1: TAF1
NewF TCTGCGATGAAAAACTCAAAGA; TAF1NewR
TCCACATCAGAGTCACTTCCA; DPM2: F CAGACCAA
GCAGTAGGATTT; R ACAAACAGGAGCAGCAGGAG;
RALGPS1: F AGTCCCCAGACACAGGAAGA; R TCTCA
GAGGCCCCTCCAT; PB1: F TGGCTACATTTTGTTCAG
CAG; R ATGGGGGCTACTCCTTGATT.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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